Standard Azithromycin Dosing

Phase 3

AAlexa Henderson

Standard Azithromycin Dosing is one of 6 therapeutic programs targeting Pre-Term. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Pre-TermRecruiting

Pre-TermPhase 3

Recruiting

Competition

Competitive Landscape

6 competitors in Pre-Term

#DrugCompanyPhaseTrials

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 2

Citicoline

UUniversity of Texas Southwestern Medical Center

Phase 3

1 3

Standard Azithromycin Dosing

AAlexa Henderson

Phase 3

1 4

L-Carnitine

IIperboreal Pharma Srl

Preclinical

1 5

Blood Puncture Site

AAssistance Publique Hopitaux De Marseille

Preclinical

1 6

Infasurf

RRoberta Ballard

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

ApprovedRecruiting

Pre-Term

NCT07669207

Clinical

Trials by Indication[1]

Pre-Term1 trial

Extended Azithromycin Treatment in Peri-viable and Extremely Preterm Prelabor Rupture of Membranes: A Pilot Study

Recruiting·AAlexa Henderson·Approved·NCT07669207·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Standard Azithromycin Dosing. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Standard Azithromycin Dosing. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Alexa Henderson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: AAlexa Henderson

Standard Azithromycin Dosing

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Pre-Term1 trial

References

Drug Info

Quick Facts

Related News